Fig. 6: Therapeutic efficacy evaluation of TYR-activated anti-cancer prodrugs in a mouse drug-resistant melanoma model.

a Experimental schedule of TYR-catalyzed intracellular prodrug activation for treating drug-resistant B16F10 melanoma on a mouse model. b Tumor growth curves of DR-B16F10 melanoma-bearing mice treated with different groups (PBS, Gel, Cd@Gel and Pd1-Pd2-SA@Gel, n = 7 mice; Pd1-Pd2-SA, n = 6 mice). Data are presented as mean ± standard error (SEM). The statistical analysis was conducted between Cd@Gel and Pd1-Pd2-SA@Gel on day 15 using two-way ANOVA followed by Dunnett’s multiple comparisons test. ****P < 0.0001. c Survival curves of the DR-B16F10-bearing mice treated with different treatment groups. Data are analyzed with the Log-rank (Mantel-Cox) test (n  =  7 mice). d Body weight changes during the treatment course (PBS, Cd@Gel and Pd1-Pd2-SA@Gel, n = 7 mice; Gel, Pd1-Pd2-SA, n = 6 mice). Data are presented as mean ± standard deviation (SD). P = 0.0002. e TUNEL staining of the tumor tissues post-treatment. (n  =  3 independent samples). f Representative images of H&E-staining of the tumor tissues post-treatment. (n  =  3 independent samples). g Complete blood count analysis of the blood from mice treated with PBS and Pd1-Pd2-SA@Gel. (WBC White Blood Cell Count, HGB Hemoglobin, RBC Red Blood Cell Count, HCT Hematocrit, MCV Mean Corpuscular Volume, PLT Platelet Count, MCH Mean Corpuscular Hemoglobin, MCHC Mean Corpuscular Hemoglobin Concentration.) (n = 6, biologically independent mice). Data are presented as mean ± standard deviation (SD). Statistical analysis was performed via unpaired Student’s t-test (two-tailed). h Liver (ALT Alanine Transaminase, AST Aspartate Transaminase) and kidney (CREA Creatinine) function analysis after PBS or Pd1-Pd2-SA@Gel treatments in mice. (n = 3 mice). Data are presented as mean ± standard deviation (SD). Statistical analysis was performed via unpaired Student’s t-test (two-tailed). (ns. not significant, ***P  <  0.001).